All In Biotech

Drug Trial Radar · NCT07897721

A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

268

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Mar 22, 2030

Study completion Mar 21, 2032

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients. This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery. All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.

Conditions

  • Advanced Breast Cancer
  • Advanced or Metastatic Breast Cancer
  • Metastatic Breast Cancer (HR+/ HER2-)
  • Metastatic Colorectal Adenocarcinoma

Interventions

  • PF-08165784Drug

    Taken by mouth (PO)

  • FulvestrantDrug

    Selective Estrogen Receptor Degrader (SERD)

  • AtirmociclibDrug

    Selective CDK4 inhibitor

  • CetuximabDrug

    Monoclonal antibody (EGFR inhibitor)

  • LetrozoleDrug

    Nonsteroidal aromatase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)Time frame: Baseline up to 28 days
  2. Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
  3. Part 1 (Dose Escalation): Number of participants with laboratory abnormalitiesTime frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
  4. Part 2 (Dose Expansion): Objective Response Rate (ORR)Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas

  • Highlands Oncology Group, PA

    Rogers, Arkansas

  • Highlands Oncology Group, PA

    Springdale, Arkansas

  • START Midwest, LLC

    Grand Rapids, Michigan

  • Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.